Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 1Phase 2 Interventional

LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive Impairment

ClinicalTrials.gov ID: NCT07934186

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07934186. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 10:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study to Establish Safety, Tolerability and Feasibility of LM11A-31 as a Neuroprotective Agent in Aging People Living With HIV and Neurocognitive Impairment on Antiretroviral Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

HIV rapidly infects the nervous system resulting in chronic infection that persists even when blood HIV is undetectable. The resulting inflammation causes progressive neuronal damage leading to cognitive decline in up to 50% of people living with HIV. The damage to the nervous system is due in part to a loss of natural processes that protect the brain. There are currently no effective treatments. A novel new drug, LM11A-31, has been shown to restore the protective processes thereby shifting the balance from degenerative to protective activity. Beneficial effects have been seen in patients with Alzheimer's disease and research indicates that it should have similar beneficial effects in people living with HIV. The proposed study will establish the safety and tolerability of LM11A-31 treatment in a small cohort of stable virally-suppressed participants with HIV and mild neurocognitive impairment. The focus will be on individuals 50-75 years of age who are most vulnerable for cognitive decline. To provide sufficient time to stabilize brain activity, participants will take tablets twice daily over a period of 48 weeks. The main focus of the trial will be on safety but will also be supplemented with exploratory characterization of biomarkers to confirm a reduction in degeneration as well as to provide early identification of individuals at risk for neurodegeneration. These studies are expected to show that LM11A-31 is safe to use in people living with HIV and to provide preliminary data indicating protection from neuronal damage and cognitive decline.

Study identification

NCT ID
NCT07934186
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Enrollment
68 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2026 (Estimated)
Primary completion
Apr 30, 2029 (Estimated)
Completion
Apr 30, 2029 (Estimated)
Last update posted
Nov 12, 2026

2026 – 2029

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
University of North Carolina School of Medicine, Clinical and Translational Research CenterUnit Chapel Hill North Carolina 27599 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07934186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 12, 2026 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.